Premium
Depotentiation of intact rat cardiac muscle unmasks an Epac‐dependent increase in myofilament Ca 2+ sensitivity
Author(s) -
Kaur Sarbjot,
Kong Cherrie HT,
Cannell Mark B,
Ward MarieLouise
Publication year - 2016
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12504
Subject(s) - myofilament , chemistry , biophysics , cardiac muscle , medicine , biochemistry , biology , actin
Summary Recently, a family of guanine nucleotide exchange factors have been identified in many cell types as important effectors of cyclic adenosine 3′,5′‐monophospahte ( cAMP ) signalling that is independent of protein kinase A ( PKA ). In the heart, investigation of exchange protein directly activated by cAMP (Epac) has yielded conflicting results. Since cAMP is an important regulator of cardiac contractility, this study aimed to examine whether Epac activation modulates excitation–contraction coupling in ventricular preparations from rat hearts. The study used 8‐(4‐chlorophenylthio)‐2′‐O‐methyladenosine‐3′, 5′‐cyclic monophosphate (cpTOME), an analogue of cAMP that activates Epac, but not PKA. In isolated myocytes, cpTOME increased Ca 2+ spark frequency from about 7 to 32/100 μ m 3 /s ( n = 10), P = 0.05 with a reduction in the peak amplitude of the sparks. Simultaneous measurements of intracellular Ca 2+ and isometric force in multicellular trabeculae ( n = 7, 1.5 mmol/L [Ca 2+ ] o ) revealed no effect of Epac activation on either the amplitude of Ca 2+ transients (Control 0.7 ± 0.1 vs cpTOME 0.7 ± 0.1; 340/380 fura‐2 ratio, P = 0.35) or on peak stress (Control 24 ± 5 mN/mm 2 vs cpTOME 23 ± 5 mN/mm 2 , P = 0.20). However, an effect of Epac in trabeculae was unmasked by lowering extracellular [Ca 2+ ] o . In these depotentiated trabeculae, activation of the Epac pathway increased myofilament Ca 2+ sensitivity, an effect that was blocked by addition of KN‐93, a Ca 2+ /calmodulin‐dependent protein kinase II (CaMK‐II) inhibitor. This study suggests that Epac activation may be a useful therapeutic target to increase the strength of contraction during low inotropic states.